Recent Progress in Glucose-Responsive Insulin

Author:

Liu Yun123,Wang Shiqi13,Wang Zejun4,Yu Jicheng12356,Wang Jinqiang1237,Buse John B.8ORCID,Gu Zhen123569ORCID

Affiliation:

1. 1State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

2. 2Jinhua Institute of Zhejiang University, Jinhua, China

3. 3Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

4. 4Department of Chemistry, College of Sciences, Northeastern University, Shenyang, China

5. 5Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

6. 6Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China

7. 7Department of Pharmacy, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China

8. 8Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC

9. 9MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou, China

Abstract

Insulin replacement therapy is indispensable in the treatment of type 1 and advanced type 2 diabetes. However, insulin’s clinical application is challenging due to its narrow therapeutic index. To mitigate acute and chronic risks of glucose excursions, glucose-responsive insulin (GRI) has long been pursued for clinical application. By integrating GRI with glucose-sensitive elements, GRI is capable of releasing or activating insulin in response to plasma or interstitial glucose levels without external monitoring, thereby improving glycemic control and reducing hypoglycemic risk. In this Perspective, we first introduce the history of GRI development and then review major glucose-responsive components that can be leveraged to control insulin delivery. Subsequently, we highlight the recent advances in GRI delivery carriers and insulin analogs. Finally, we provide a look to the future and the challenges of clinical application of GRI. Article Highlights

Funder

the Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University

JDRF

Chinese Polar Environment Comprehensive Investigation and Assessment Programmes

National Natural Science Foundation of China

Kunpeng program from Zhejiang Province

the Startup Packages of Zhejiang University

Fundamental Research Funds for the Central Universities

Publisher

American Diabetes Association

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3